

EHSF
goes Hybrid

Facing HS according to the Renaissance style



EHSF 2023

FIRENZE | FEBRUARY 8–10, 2023

12th CONFERENCE OF THE EUROPEAN
HIDRADENITIS SUPPURATIVA FOUNDATION



www.ehsf2023.com



Time to focus on HS

Embracing patients' and carers' needs for a better future.

Intended for healthcare professionals only.

© UCB Biopharma SRL, 2022. All rights reserved. Date of preparation: December 2022 IT-N-DA-HS-2200002

TABLE OF CONTENTS

01 WELCOME MESSAGE	02 ABOUT EHSF
05	Our history 06
	1 st International Hidradenitis Suppurativa Research Symposium 06
	Last HSF, Inc. Board with European Participation 06
	Inauguration of EHSF e.V. 07
	Founding Members 07
	Congresses 08
	Our Goals 08
03 COMMITTEES	04 FEBRUARY 08, 2023 PROGRAM WEDNESDAY
Organizing Committee 10	Overview 14
Scientific Committee 11	Program 15
Local Organizing Committee 12	
05 SPONSORS	06 IMPRINT
18	26

Pharmaceuticals with Passion



The company is active in the research, development, production and distribution of prescription drugs, self-medication products and nutraceuticals. Born in 2015 from the aggregation of two historical Italian pharmaceutical companies, Alfasigma has production plants, cutting-edge R&D laboratories, subsidiaries and distributors in about 90 countries worldwide. Alfasigma is committed to improving patients' health in different pathologies with a focus in the gastrointestinal area and continuous investment in innovation. Alfasigma contributes to the development of local communities by supporting social and environmental responsibility initiatives.

WELCOME MESSAGE

Dear colleagues,

We are very proud to welcome you in Florence for the 12th Conference of the European Hidradenitis Suppurativa Foundation. The Conference will be held in a hybrid mode from 8th to 10th February 2023.

First of all it is necessary to thank all the industries for making the 12th Conference of the European Hidradenitis Suppurativa Foundation a successful event.

Indeed, the industry has continued to innovate by investments in studies and research, up to development of new molecules for patients affected by hidradenitis suppurativa (HS), over the last few years. Thanks to this partnership, grown together, has been possible to promote a shared culture on new scientific and technological frontiers in the field of HS.

After years of remote events, EHSF 2023 will be an excellent opportunity to meet again in person further strengthening this partnership in support of HS patients.



Francesca Prignano, MD, PhD

Associate Professor

Dept. Health Sciences,
Div. Dermatology - University of Florence Medical School,
Firenze, Italy

ABOUT EHSF

OUR HISTORY

Founding of HSF, Inc.

In 2005, Mrs. Michele Barlow, a patient from San Diego, CA, USA, organized first funding to initiate the Hidradenitis Suppurativa Foundation, Inc. (HSF, Inc.), a tax-deducted organization according to the US law. In addition to Mrs. Barlow as president and co-founder, the first board of HSF Inc. included Mr. Robert Howes, San Diego, CA, USA, vice president and co-founder, Prof. Dr. Ralf Paus, Luebeck, Germany, director of basic research and co-founder, Prof. Dr. Christos C. Zouboulis, Dessau, Germany, director of clinical research and co-founder, Mrs. Christine E. Pasela, San Diego, CA, USA, Mrs. Sylvia Shawcross, Chelsea, Quebec, Canada, Mrs. Mary Veta, San Diego, CA, USA, and Mrs. Lynn Edward Wedell, San Diego, CA, USA. Experimental Dermatology became the official scientific journal of the HSF, Inc.

1st INTERNATIONAL HIDRADENITIS SUPPURATIVA RESEARCH SYMPOSIUM

The 1st International Hidradenitis Suppurativa Research Symposium took place on 30.03–02.04.2006 in Dessau, Germany. The milestones of the Symposium were the so-called Dessauer definition of the disease and the HSF 2006 Outstanding Investigator Award presented to Prof. Gregor B. E. Jemec. The attendees of this legendary meeting were Dr. David R. Adams, USA; Dr. Andreas Altenburg, Germany; Mrs. Michelle Barlow,

USA; Dr. Martina Brunner, Germany; Dr. George Cotsarelis, USA; Dr. William Danby, USA; Dr. Alain Dupuy, France; Dr. Sabine Fimmel, Germany; Dr. Wolfgang Hartschuh, Germany; Dr. Dolores Herreros, Spain; Dr. Dorothee Hochheim, Germany; Mr. Robert Howes, USA; Dr. Peter Hull, Canada; Dr. Gregor Jemec, Denmark; Dr. Yvonne Kroening, Germany; Dr. Ichiro Kurokawa, Japan; Dr. Hjalmar Kurzen, Germany; Dr. Evgenia Makrantonaki, Germany; Dr. Anirban Mandal, UK; Dr. Lynette Margesson, USA; Dr. Wolfgang, C. Marsch, Germany; Dr. W.H. Irwin McLean, Scotland; Dr. Samuel L. Moschella, USA; Dr. Ralf Paus, Germany; Dr. Uppala Radhakrishna, USA; Dr. Jean Revuz, France; Dr. Jihai Shi, Germany; Dr. Rodney Sinclair, Australia; Dr. John Sundberg, USA; Dr. Gilles Tachon, France; Dr. Antje Thielitz, Germany; Dr. Athanasios Theodoridis, Germany; Dr. Frangiski Tsatsou, Germany; Dr. Jan von der Werth, UK; and Dr. Christos C. Zouboulis, Germany.

LAST HSF, INC. BOARD WITH EUROPEAN PARTICIPATION

On 15.02.2012 a new HSF, Inc. board was elected (and re-elected on 11.02.2018) with Prof. Dr. Christos C. Zouboulis, Dessau, Germany, President and responsible for hidradenitis suppurativa/acne inversa guidelines, Prof. Gregor B.E. Jemec, Copenhagen, Denmark, vice president and responsible for clinical research, Prof. Dr. Ralf Paus, Luebeck, Germany/Manchester, UK, vice president and responsible for experimental research, Mrs. Michelle

Barlow, San Diego, CA, USA (former president, ex officio), treasurer and responsible for the Foundation, Prof. Richard Gallo, San Diego, CA, USA, Dr. Ichiro Kurokawa, Nishinomiya, Japan, Dr. George Varigos, Melbourne, Australia, Dr. Jan Lapins, Stockholm, Sweden, Dr. Paul Hazen, Westlake, OH, USA, responsible for patients' communication and for the HSF Inc. website, Thomas Winkler, Germany, patients' representative, president Deutsche Interessengemeinschaft Akne inversa e.V., and Dr. Hessel H. van der See, Rotterdam, The Netherlands.

Despite the excellent and close cooperation among the involved scientists, the European Board members have recognized that bureaucratic issues in the USA made it more and more difficult for non-US citizens to run efficiently a US association. Therefore, Prof. Zouboulis resigned as HSF, Inc. president and member of the board on 27.02.2013 followed by Prof. Paus, leaving the leadership of the HSF, Inc. to US colleagues with Dr. Paul Hazen as new HSF, Inc. president from 02.03.2013. During its first meeting on 24.03.2014 the new HSF, Inc. board has granted Mrs. Michelle Barlow, Prof. Christos C. Zouboulis and Prof. Ralf Paus the honorary Founders HSF, Inc. membership.

INAUGURATION OF EHSF E.V.

The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) has been inaugurated on 29.09.2012 in Prague, Czech Republic as independent, sister society of

HSF, Inc. The EHSF e.V. has been registered and recognized as a non-profit, public benefit organization (gemeinnütziger e.V.) according to the German law. General assemblies, take place annually during the annual International Conference of the Society.

FOUNDING MEMBERS

- Dr. Jurr Boer, Deventer/The Netherlands
- Prof. Dr. Veronique del Marmol, Brussels/Belgium
- Dr. Nemesha Desai, London/United Kingdom
- Dr. Deirdre Nathalie Dufour, Kalundborg/Denmark
- Dr. Lennart Emtestam, Stockholm/Sweden
- Prof. Dr. Gregor B.E. Jemec, Roskilde/Denmark
- Dr. Łukasz Matusiak, Wrocław/Poland
- Prof. Dr. Thrasivoulos Tzello, Harstad, Troms/Norway
- Thomas Winkler, Lüdinghausen/Germany
- Dr. Hessel H. van der Zee, Rotterdam/The Netherlands
- Prof. Dr. Christos C. Zouboulis, Dessau-Rosslau/Germany

CONGRESSES

The 2nd International Hidradenitis Suppurativa Research Symposium took place on 05.03.2009 in San Francisco, IL, USA.

The 3rd International Hidradenitis Suppurativa Research Symposium (first of the EHSF e.V.) took place on 27.-28.02.2014 in Brussels, Belgium.

The 4th International Hidradenitis Suppurativa Research Symposium took place on 19.-20.02.2015 in Brussels, Belgium.

The 5th International Hidradenitis Suppurativa Conference, which was for the first time also open for non-members of the Society, took place on 10.-12.02.2016 in Berlin, Germany with 192 participants and 76 scientific contributions.

The 6th International Hidradenitis Suppurativa Conference took place on 8.-10.02.2017 in Copenhagen, Denmark with 202 participants and 77 scientific contributions.

The 7th International Hidradenitis Suppurativa Conference took place on 10.-12.02.2018 in Rotterdam, The Netherlands with more than 250 participants and 82 scientific contributions.

The 8th International Hidradenitis Suppurativa Conference took place on 10.-12.02.2019 in Wrocław, Poland with 406 participants and 119 scientific contributions.

The 9th International Hidradenitis Suppurativa Conference took place on 5.-7.02.2020 in Athens, Greece. 422 participants from 48 countries with 137 scientific contributions participated at the conference.

The 10th International Hidradenitis Suppurativa Conference took place – due to the COVID-19 pandemic – at a digital mode – 10.-12.02.2021. 138 scientific contributions were presented and 688 participants from 52 countries took part.

The 11th International Hidradenitis Suppurativa Conference took place – due to the COVID-19 pandemic – at a digital mode – 09.-11.02.2022. 138 scientific contributions were presented and 598 participants from 48 countries took part. with 12% of the participants were young scientists under the age of 30 years, a fact that guarantees a wide future of dermatology in the field of hidradenitis suppurativa.

The 12th International Hidradenitis Suppurativa Conference takes place hybrid from February 8-10, 2023 in Firenze.

OUR GOALS

- The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) pursues exclusively and directly charitable purposes within the meaning of the “tax-privileged purposes” of the tax code. Goal of the association is the promotion of science and research in field of the disease hidradenitis suppurativa/acne inversa.
- The goal of the association is raising funds for the promotion of research projects in the field of the disease hidradenitis suppurativa/acne inversa also to be achieved by support from other tax-exempt entities, public corporations or foreign entities whose activity is in line with the German Charity Law.

- Goal of the association is also the training of physicians, patients and laypersons.
- These goals are to be achieved
 - through raising funds for the support of scientific meetings for education of physicians, patients and laypersons also from other tax-exempt bodies, public corporations or foreign corporations whose business is through raising funds for the support of scientific meetings for continuing education of physicians, patients and laypersons in accordance with the German Charity Law,
 - through lectures of educational character and
 - through public relations. Goal of the association is also raising funds for the promotion of public health care in the field of the disease hidradenitis suppurativa/acne inversa also from other tax-exempt entities, public corporations or foreign corporations whose activities are in line with the German non-profit law.



cantabria labs
DIFA COOPER

EHSF ORGANIZING COMMITTEE



FRANCESCA PRIGNANO

(Firenze, Italy)



GREGOR B.E. JEMEC

(Roskilde, Denmark)



VERONIQUE DEL MARMOL

(Brussels, Belgium)



ANGELO V. MARZANO

(Milan, Italy)



ERROL P. PRENS

(Rotterdam, The Netherlands)



THRASYVOULOS TZELLOS

(Bodø, Norway)



CHRISTOS C. ZOUBOULIS

(Dessau, Germany)



The Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium; the Department of Dermatology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark; the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany; and the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands are health care providers of the European Reference Network of Rare and Complex Skin Diseases (ERN Skin)

SCIENTIFIC COMMITTEE

Afsaneh Alavi

Erkan Alpsoy

Matthias Augustin

Edileia Bagatin

Falk Bechara

Pierre-André Becherel

Farida Benhadou

Vincenzo Bettoli

Yousef Binamer

Jurr Boer

Raffaele D. Caposiena Caro

Nisha S. Chandran

Arnon D. Cohen

Veronique Del Marmol

Maïa Delage-Toriel

Antonella Di Cesare

Alireza Firooz

John W. Frew

Ruta Ganceviciene

Simone Garcovich

Evangelos J. Giamarellos-Bourboulis

Katalin Glasenhardt

Matthias Goebeler

Noah Goldfarb

Philippe Guillem

Wayne Gulliver

Ariela Hafner

Iltefat Hamzavi

Yuval Hilerowicz

Barbara Hórvath

Evgenia Hristakieva

Robert E. Hunger

John R. Ingram

Dimitrios Ioannidis

Gregor B.E. Jemec

Olivier Join-Lambert

Qiang Ju

Alexander Katoulis

Lajos Kemény

Alexa B. Kimball

Brian Kirby

Joslyn S. Kirby

Nathalie Kirsten

Ishiro Kurokawa

Hjalmar Kurzen

Athanasios Kyrgidis

Michelle Lowes

Antonio Martorell

Angelo V. Marzano

Łukasz Matusiak

Dillon Mintoff

Alejandro Molina-Leyva

Haley Naik

Aude Nassif

Georgios Nikolakis

Hazel H. Oon

José C. Pascual Ramirez

Andreas Pinter


Maurizio Podda

Errol P. Prens

Dagmar Presser
Francesca Prignano
Luis Puig
Tadas Raudonis
Ziad Reguai
Jorge Romani
Marco Romanelli
Elia Rosi
Ditte M. Saunte
Christopher J. Sayed
Rodney Sinclair
Dae H. Suh
Andrea Szegedi
Jacek C. Szepietowski
Sylke Schneider-Burrus
Terui Tadashi
Linnea Thorlacius
Ann-Marie Tobin
Frangkiski Tsatsou
Thrasyvoulos Tzellos
Skaidra Valiukeviciene
Hessel H. van der Zee
Kelsey R. Van Straalen
Eva Vilarrasa
Esther von Stebut
Eva Vilarrasa
Seçil Vural
Baoxi Wang
Pierre Wolkenstein
Ximena Wortsman
Christos C. Zouboulis

LOCAL ORGANIZING COMMITTEE

Francesca Prignano
Nicola Pimpinelli
Elia Rosi
Antonella Di Cesare



We chase the *miracles*
of science to improve
people's lives

We are Sanofi


We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives.

Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.

We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

sanofi

WEDNESDAY PROGRAM OVERVIEW

 Wednesday, February 08, 2023

08.00–19.00 (CET)

Sponsor Exhibition (digital booths) – Meetings with Sponsor Representatives

 09.00–10.00 (CET)

Novartis Satellite Symposium

 10.00–11.30 (CET)

AbbVie Satellite Symposium

 12.45–13.30 (CET)

UCB Satellite Symposium

 14.00–15.30 (CET)

AbbVie Satellite Symposium

12th EHSF Conference Abstract Book
Poster Viewing

EHSF 2023 is a hybrid event. Join us on-site in Florence, Italy, or digitally at <https://conference.ehsf2023.com/>

09.00–10.00

Novartis Satellite Symposium

Hide and Seek: A look into future technology-assisted tools and novel approaches for the management of HS

John Ingram, Cardiff University

Amit Garg, Feinstein Institute for Medical Research

Antonio Martorell, Manises Hospital, Valencia

Francesca Prignano, University of Florence

 All day

12th EHSF
Conference
Abstract Book

 All day

Poster Viewing
on site and on
the platform

10.00–11.30

AbbVie Satellite Symposium

Delayed diagnosis and treatment in HS: Managing advanced disease

Hessel Van der Zee, Erasmus University Rotterdam

Monika Arenbergerova, Charles University Prague

Falk Bechara, Ruhr University Bochum

Pierre-André Bécherel, Hopital privé d'Antony

Vincenzo Bettoli, University of Ferrara

Lukasz Matusiak, Wroclaw Medical University

Saxon Smith, Gosfor and St Leonard's Hospitals

12.45–13.30

UCB Satellite Symposium

Exploring the patient journey: why time matters

Francesca Prignano, University of Florence

John Ingram, Cardiff University

Andreas Pinter, Goethe University Frankfurt am Main

14.00–15.30

AbbVie Satellite Symposium

Early diagnosis and treatment in HS: Maximising outcomes

Wayne Gulliver, Memorial University of Newfoundland, Canada

Antonio Martorell, Hospital Manises

Maria Rivitti-Machado, University of Sao Paulo

Laura Savage, Leeds Teaching Hospitals NHS Trust

Mariano Suppa, Hopital Académique ERASME

Thrasylvoulos Tzello, University hospital of North Norway



BioNike
SALUTE E BELLESSERE



ALWAYS *with you*

EHSF SPONSORS

We would like to thank all our sponsors for their support and are looking forward to further collaboration!

Platinum Sponsor

ABBVIE

www.abbvie.com

abbvie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions, such as hidradenitis suppurativa.

Gold Sponsor

NOVARTIS

www.novartis.com

 NOVARTIS

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at <https://www.novartis.com>

UCB

www.ucb.com

 Inspired by patients.
Driven by science.

UCB's ambition is to transform the lives of people living with severe diseases. We focus on neurological and immunological disorders.

UCB is working to advance science and embrace new knowledge. We leverage scientific advances in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs and practical solutions.

Silver Sponsor

BOEHRINGER INGELHEIM

www.boehringer-ingelheim.com

 Boehringer
Ingelheim

INCYTE

www.incyte.com

 Incyte

Other Sponsors

ALMIRALL

www.almirall.com

Almirall is a leading skin-health focused global pharmaceutical company based in Barcelona that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions to where they are needed most.

AMGEN

www.amgen.com

A biotechnology pioneer since 1980, Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of unmet medical need and leverages its expertise to improve health outcomes and people's lives.

Other Sponsors

ELI LILLY ITALY**www.lilly.com**

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.

We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Immunology is one of Lilly's five core disease areas – Lilly is committed to providing treatments that make life better for those living with skin related diseases.

JANSSEN ITALY**www.janssen.com**

Janssen Italy is the Pharmaceutical Company of Johnson & Johnson. With over 1,500 employees, Janssen Italia is located in this country since 1975. Headed by Mario Sturion, Managing Director, the company is expanding its pipeline with 14 new molecules to be launched by 2025. We are focused on areas of medicine where we can make the biggest difference: Oncology; Immunology; Infectious Diseases & Vaccines; Neuroscience; Cardiovascular, Metabolism & Retina; and Pulmonary Hypertension.

MOLTENI THERAPEUTICS**www.moltenitherapeutics.it**

Molteni Therapeutics is a spin-off company of Molteni Farmaceutici, a pharmaceutical firm based in Florence since 1892. Molteni Therapeutics is dedicated to the development of innovative Medical Devices, mainly based on the PhotoDynamic Therapy (PDT), in the field of wound care.

Molteni Therapeutics offers a promising therapeutic modality intended to accelerate wound healing and tissue repair for the treatment of infected skin wounds and ulcers.
info@moltenitherapeutics.it

SANOFI**www.sanofi.it**

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives.

Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

UNIFARCO**www.ceramol.com**

Unifarco Biomedical leads the field in the treatment of skin problems, offering a complete range of dermatological cosmetics and medical devices to treat dermatitis and sensitive skin, also suitable for babies. We have studied the skin barrier for more than 30 years, coming up with new solutions for atopic, allergic, intolerant and reactive skin. Our research laboratories work closely with dermatologists, researchers and pharmacists to develop highly innovative dermatological cosmetics that are kind to even the most sensitive skin.

ABIOTEN**BIODUE****BIOTEN ITALIA****BIONIKE****DIFA COOPER – CANTABRIA LABS****LEO PHARMA ITALY****NOVARTIS ITALY**



February 07-09, 2024

13TH CONFERENCE OF THE EUROPEAN
HIDRADENITIS SUPPURATIVA FOUNDATION



EHSF IMPRINT

Scientific Organizer

European Hidradenitis Suppurativa
Foundation e.V.
Auenweg 38, 06847 Dessau-Rosslau
www.ehsf.eu

Prof. Dr. Christos C. Zouboulis
President of the EHSF e.V.

Professional Congress Organizer

MCI Deutschland GmbH
Markgrafenstrasse 56
10117 Berlin
T: +49 30 20459230
F: +49 30 2045950

Congress venue

Firenze Fiera S.p.A.
Congress & Exhibition Center
Sede Legale e Operativa: Piazza Adua, 1
50123 Firenze (Italy)

Contact

Project Management
Viktoria Solotar
T: +49 30 20459374
ehsf@wearemci.com

Sponsoring/Exhibition
Kristina Van Cleave
T: +49 30 20459469
ehsf-sponsoring@wearemci.com



where
science meets **humanity**™



Chronic neurologic diseases and inflammatory autoimmune diseases affect the lives of many patients and their caregivers. At Biogen we renew everyday our commitment to people, by pioneering new science and by answering the need for sustainability of healthcare systems.

Our mission is to serve humanity through science, and we are dedicated to improving people's lives by developing innovative and accessible therapies.

[Biogen.com](https://www.biogen.com)



Caring Deeply. Working Fearlessly. Changing Lives.

abbvie SYMPOSIA SERIES

HS Management within the 'Window of Opportunity': impacts of delayed and early diagnosis and treatment

Wednesday 8th February 2023

Join us live or virtually at 2 symposia to learn from 13 international dermatology experts about the impacts of delayed and early Hidradenitis Suppurativa (HS) diagnosis and treatment on adolescent patient case studies.

Watch in Main Auditorium or watch live online.
Replays will be available after live event

SYMPOSIUM 1

**DELAYED DIAGNOSIS
AND TREATMENT
IN HS:
MANAGING
ADVANCED DISEASE**

10:00-11:30 (CET)

Main Auditorium or
watch online on the
EHSF platform

Dr. Hessel van der Zee (Netherlands)
Dr. Monika Arenbergerova (Czechia)
Dr. Falk Bechara (Germany)
Dr. Pierre-André Bécherel (France)
Dr. Vincenzo Bettoli (Italy)
Dr. Lukasz Matusiak (Poland)
Dr. Saxon Smith (Australia)

SYMPOSIUM 2

**EARLY DIAGNOSIS AND
TREATMENT
IN HS:
OPTIMIZING
OUTCOMES**

14:00-15:30 (CET)

Main Auditorium or
watch online on the
EHSF platform

Dr. Wayne Gulliver (Canada)
Dr. Maria Rivitti Machado (Brazil)
Dr. Antonio Martorell (Spain)
Dr. Laura Savage (UK)
Dr. Mariano Suppa (Belgium)
Dr. Thrasyvoulos Tzellos (Norway)